SCARD Pool report for 01-01-2002 to 31-12-2002

Participants	Doctors	2	
	Patients	48	
Specimens	New lesions	88	77.88%
	Previously biopsied lesions	25	22.12%
	Total lesions	113	100.00%

Breakdown of new versus previously biopsied specimens



Percentage of new lesions tested which were malignant	74.71%
Percentage of Definitively excised lesions that were malignant	79.31%
Lesions tested to find one melanoma (NNT)	5.00
Percentage of lesions tested for NMSC which were NMSC	80.00%
Ratio of New BCCs : New Melanomas	44:1

Accuracy

Diagnostic sensitivity

Melanomas	100.00% of 1
All NMSC	93.75% of 64
BCCs	90.91% of 44
SCCs	60.00% of 20

Positive predictive value

Melanomas	100.00% of 1
All NMSC	85.71% of 70
BCCs	57.14% of 70
SCCs	63.16% of 19

Adequacy

Percentage of definitively managed malignant cases where surgical margins were adequate


BCC	73.68% of 19
IEC/Bowens disease	100.00% of 5
SCC	83.33% of 6
Keratoacanthoma	0% of 0
Melanoma - in situ	0% of 0
Melanoma - invasive	0% of 0
Melanoma - invasive > 1mm	0% of 0
Other malignant	0% of 0

© 2026 SCARD Systems Pty Ltd

Lesion Breakdown

Histological Diagnosis

BCC (unspecified type)	11	12.50%
BCC - Superficial	16	18.18%
BCC - Nodular/Solid	13	14.77%
BCC - Aggressive	4	4.55%
IEC/Bowens disease	15	17.05%
SCC	5	5.68%
Keratoacanthoma	0	0%
Pinkus Fibroepithelioma	0	0%
Merkel cell tumour	0	0%
Other malignant	0	0%
NMSC Metastasis	0	0%
Melanoma - in situ	1	1.14%
Melanoma - invasive	0	0%
Melanoma - invasive > 1mm	0	0%
Melanoma - metastasis	0	0%
MELTUMP	0	0%
Naevus - other	2	2.27%
Naevus - dysplastic/Clark	1	1.14%
Naevus - blue	0	0%
Naevus - Spitz/Reed	0	0%
Naevus - Compound	0	0%
Solar keratosis	8	9.09%
Solar lentigo	0	0%
Seborrhoeic keratosis	7	7.95%
Lentigo Simplex	0	0%
Lichenoid keratosis (LPLK)	0	0%
Dermatofibroma	0	0%
Sebaceous gland hyperplasia	0	0%
Benign cyst	0	0%
Other benign	4	4.55%
Histology Pending	0	0%



© 2026 SCARD Systems Pty Ltd

Procedures

Definitive Surgical Management used to exclude melanoma

Ellipse	1	50.00%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Curettage & Cautery	1	50.00%
Liquid N2 freeze/thaw	0	0%
PDT	0	0%
Imiquimod	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	0	0%
Other	0	0%

Biopsy used to exclude melanoma

Punch - sample	2	66.67%
Shave - sample	0	0%
Incisional	0	0%
Punch - removal	0	0%
Shave - removal	0	0%
Excisional	1	33.33%
Curettage	0	0%
Other	0	0%

Breakdown of definitive management procedures for malignant conditions

Ellipse	32	35.96%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	1	1.12%
Curettage & Cautery	43	48.31%
Liquid N2 freeze/thaw	1	1.12%
PDT	0	0%
Imiquimod	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	12	13.48%
Other	0	0%

Breakdown of definitive management procedures for benign conditions

Ellipse	1	7.14%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Liquid N2 freeze/thaw	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	0	0%
Other	1	7.14%

© 2026 SCARD Systems Pty Ltd

Procedures (continued)


Percentage of procedures/closures that were complex

Complex Closures	0% of 2
Complex Closures (inc Curettage & Cautery)	0% of 14

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

Nose	0	0% of 2
Lip	0	0% of 1
Ear	0	0% of 7
Eyelid	0	0% of 1
Other face	0	0% of 24
Scalp	1	20.00% of 5
Neck	0	0% of 5
Shoulder	0	0% of 1
Chest	0	0% of 4
Abdomen	0	0% of 0
Genitalia	0	0% of 0
Back	0	0% of 4
Buttock	0	0% of 0
Arm	0	0% of 5
Forearm	0	0% of 14
Hand Dorsal	0	0% of 5
Hand Palmar	0	0% of 0
Finger Dorsal	0	0% of 1
Finger Nail	0	0% of 0
Finger Palmar	0	0% of 0
Thigh	0	0% of 0
Leg	0	0% of 9
Foot Dorsal	0	0% of 0
Foot Plantar	0	0% of 0
Toe Dorsal	0	0% of 0
Toe Nail	0	0% of 0
Toe Plantar	0	0% of 0
Palm Or Sole	0	0% of 0



© 2026 SCARD Systems Pty Ltd